Post Market Report: Sensex, Nifty and record run continues; Zydus, HAL, Dalmia, NLC in focus

Benchmark equity indices closed higher with logged 7 straight days high, as the bullish momentum continued with buying in information technology and power names and continuous foreign inflow took the benchmarks to a new high for a third day.

In broader markets, the BSE midcap and Smallcap indices ended marginally higher.

The Indian rupee ended higher by 6 paisa at around 83.32 against the US dollar on Wednesday.

Stock in News Today

Zydus Lifesciences: The pharma giant has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Methylene Blue Injection.

Hindustan Aeronautics Ltd (HAL): The public sector aerospace and defense company will demonstrate stride made in achieving self-reliance in avionics to its stakeholders, including the Indian armed forces, at the two-day event. The share price rose to 75 during the day. 

Dalmia Bharat: The Board of Directors of the company, has appointed Puneet Yadu Dalmia as Managing Director & CEO for 5 years with effect from December 8, and Mahendra Singhi as Strategic Advisor to Managing Director & CEO with effect from December 9.

NLC India: The power company has started a bio-mass co-firing operation in its coal-based thermal power station NLC Tamilnadu Power (NTPL) at Tuticorin. 

Hero Motocorp: Hero MotoCorp and Ather Energy have entered into a partnership for an interoperable fast-charging network in India. Through this collaboration, EV users will be able to seamlessly use both VIDA and Ather Grids across the country. The combined network will cover 100 cities with over 1900 fast charging points. 

Angel One: The company’s client base rose to 1.85 crore in November, reflecting a nearly 4 percent rise as compared to the previous month. Number of orders also rose 51.4 percent on year to 10.72 crore. Share price reaches 52 52-week high. 

SBI Life Insurance Company: The company bought 20 lakh shares in Swan Energy and Europe-based financial services company Societe Generale purchased 18 lakh shares in the firm at an average price of Rs 414 per share, which in total amounted to Rs 157.32 crore.

Orchid Pharma: The board approves draft approved a draft Scheme of Amalgamation and Arrangement between Dhanuka Laboratories and their respective shareholders and creditors.

Indoco Remedies: The pharma company announced the receipt of tentative approval from the USFDA for an Abbreviated New Drug Application (ANDA) for Canagliflozin Tablets 100 mg and 300 mg, a generic equivalent of the Reference Listed Drug, Invokana Tablets 100 mg and 300 mg, of Janssen Pharmaceuticals, Inc.